BCOP Exam Real Questions And Answers| Latest Update Guaranteed Success
Belzutifan Indication, MOA, AE VHL associated cancer not requiring immediate surgery
HIF inhibitor
Anemia, hypoxia, fetal harm, vision problems, hyperglycemia, nausea
Tivozanib MOA indication AE VEGF inhibitor
HTN, stomatitis, diarrhea, anorexia, dysphonia, hypothyroidism
R/R RCC after 2 lines of therapies
DPD deficiency and 5FU antidote Increased 5FU toxicity
Uridine triacetate- antidote for 5FU overdose, give within 96 hours from the end of infusion
UGT1A1 Increase irrinotecan toxicity (neutropenia)
Reduce dose if UGT1A1*28 homozymous
Continuous 5FU in CRC AE Inhibit TS, more HFS and mucositis
FOLFOX versus FOLFIRI toxicity FOLFOX (5FU, OXA): more neurotoxicity, neutropenia,
thrombocytopenia
FOLFIRI: more FN, mucositis, diarrhea, alopecia
Regorafanib MOA, AE Multi-targeted kinase inhibitor (including VGFR)
HFS/ rash, diarrhea, HTN
Take following low fat meat (<30% fat, 600 cal)
Trifuridine/ tipiracil (Lonsurf) AE Myelosuppression
~5FU
, Tremelimumab MOA Anti-CTLA4
Risk factor for oropharyngeal and nasopharyngeal cancer Oro: HPV 16, P16 required at
diagnosis. Prevented by HPV vaccine
Naso: EBV; consider HBV DNA monitoring
What cancers can be prevented by smoking cessation? Lung, HNE, esophagus cancer
Vandetanib MOA, AE, indication EGFR/ VEGF/ RET multi-kinase inhibitor
Medullary thyroid cancer
Qtc prolongation, HTN, decreased appetite, diarrhea, rash
Erdafitinib MOA, indication, AE FGFR inhibitor
FGFR 2/3 (+) bladder cancer, R/R subsequent
Hyponatremia, stomatitis, fatigue
Enfortumab MOA, indication, AE ADC: Nectin-4 directed with anti-microtubule
R/R MIBC (bladder) s/p platinum and pembro
neuropathy, N/V/D, rash
Sacituzumab MOA, AE, indication ADC: top 1 inhibitor linked to trop 2 monoclonal antibody
Last line MIBC (bladder)
mBC TN
AE: neutropenia, diarrhea
Sunitinib AE skin discoloration, nausea, diarrhea, fatigue.
Belzutifan Indication, MOA, AE VHL associated cancer not requiring immediate surgery
HIF inhibitor
Anemia, hypoxia, fetal harm, vision problems, hyperglycemia, nausea
Tivozanib MOA indication AE VEGF inhibitor
HTN, stomatitis, diarrhea, anorexia, dysphonia, hypothyroidism
R/R RCC after 2 lines of therapies
DPD deficiency and 5FU antidote Increased 5FU toxicity
Uridine triacetate- antidote for 5FU overdose, give within 96 hours from the end of infusion
UGT1A1 Increase irrinotecan toxicity (neutropenia)
Reduce dose if UGT1A1*28 homozymous
Continuous 5FU in CRC AE Inhibit TS, more HFS and mucositis
FOLFOX versus FOLFIRI toxicity FOLFOX (5FU, OXA): more neurotoxicity, neutropenia,
thrombocytopenia
FOLFIRI: more FN, mucositis, diarrhea, alopecia
Regorafanib MOA, AE Multi-targeted kinase inhibitor (including VGFR)
HFS/ rash, diarrhea, HTN
Take following low fat meat (<30% fat, 600 cal)
Trifuridine/ tipiracil (Lonsurf) AE Myelosuppression
~5FU
, Tremelimumab MOA Anti-CTLA4
Risk factor for oropharyngeal and nasopharyngeal cancer Oro: HPV 16, P16 required at
diagnosis. Prevented by HPV vaccine
Naso: EBV; consider HBV DNA monitoring
What cancers can be prevented by smoking cessation? Lung, HNE, esophagus cancer
Vandetanib MOA, AE, indication EGFR/ VEGF/ RET multi-kinase inhibitor
Medullary thyroid cancer
Qtc prolongation, HTN, decreased appetite, diarrhea, rash
Erdafitinib MOA, indication, AE FGFR inhibitor
FGFR 2/3 (+) bladder cancer, R/R subsequent
Hyponatremia, stomatitis, fatigue
Enfortumab MOA, indication, AE ADC: Nectin-4 directed with anti-microtubule
R/R MIBC (bladder) s/p platinum and pembro
neuropathy, N/V/D, rash
Sacituzumab MOA, AE, indication ADC: top 1 inhibitor linked to trop 2 monoclonal antibody
Last line MIBC (bladder)
mBC TN
AE: neutropenia, diarrhea
Sunitinib AE skin discoloration, nausea, diarrhea, fatigue.
